Implementing the EU’s Falsified Medicines Directive – new line of INFAI packaging
The EU’s Falsified Medicines Directive (2011/62/EU) has been in force since February 9, 2019. The directive is expected to protect the well-being of patients by putting an end to the criminal counterfeiting of medicine
INFAI is currently conducting the following clinical studies.
Study PPI; Eudra CT Number: 2017-001369-25
The Sensitivity and Specificity in Helicobacter Pylori Positive and Negative Patients with Dyspesia Taking Proton Pump Inhibitors. Sponsor: INFAI
INFAI will participate in the 28th UEG (United European Gastroenterology) Week, October 10-15, 2020, in Amsterdam, the Netherlands.
The exhibition will take place at RAI Amsterdam.
INFAI at the European Helicobacter and Microbiota Study Group (EHMSG)
INFAI will be present at the European Helicobacter and Microbiota Study Group (EHMSG) – XXXIVth Workshop of the European Helicobacter and Microbiota Study Group – EHMSG 2021
Belgrade Serbia | September 16 – 18, 2021
INFAI will participate in HealthPlusCare in London UK, June 24-25, 2020.
The exhibition will take place at ExCeL London.
INFAI will participate in the BSG (British Society of Gastroenterology) Annual Meeting in Liverpool, UK, June 15-18, 2020.
The exhibition will be held at ACC Liverpool.
Riehler Straße 36
D-50668 Cologne, Germany
Phone: +49 221 880 44-3
Fax: +49 221 880 44-55
24h Notrufnr.: +49 177 33 49 660
E-Mail: mail@infai.de
Universitätsstraße 136
D-44799 Bochum, Germany
Phone: +49 234 971130
Telefax: +49 234 9711325
E-Mail: mail@infai.de
Niederlassung Hagen
An der Kohlenbahn 39
D-58135 Hagen, Germany
Phone: +49 2331 349 310
Fax: +49 2331 349 31-25
E-Mail: mail@infai.de